Patients having a poor metabolism phenotype will have an increased elimination of the active drug

The statement is actually incorrect. Patients with a poor metabolism phenotype will not have an increased elimination of the active drug. Instead, they will have a decreased elimination of the drug.

Here's why:

1. Metabolism is the process by which the body breaks down and eliminates substances. In the context of drugs, this process can convert active drugs into inactive forms, which are then eliminated from the body.

2. A poor metabolism phenotype means that a person's body is less efficient at this process. This could be due to genetic factors, or due to damage or disease affecting the liver, where most drug metabolism occurs.

3. Therefore, if a person has a poor metabolism phenotype, their body will be slower to break down and eliminate drugs. This means that the active form of the drug will stay in their system for longer.

4. This can potentially increase the risk of drug toxicity, as the active drug continues to have an effect on the body for a longer period of time. It can also affect the dosing of the drug, as a lower dose may be needed to avoid toxicity.

5. So, rather than increasing the elimination of the active drug, a poor metabolism phenotype will actually decrease it.